Pfizer–BioNTech-ის COVID-19-ის საწინააღმდეგო ვაქცინა (Georgian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Pfizer–BioNTech-ის COVID-19-ის საწინააღმდეგო ვაქცინა" in Georgian language version.

refsWebsite

Global rank Georgian rank

27nih.gov

4^th place

8^th place

20web.archive.org

1^st place

13doi.org

2^nd place

7^th place

5fda.gov

447^th place

1,705^th place

5cdc.gov

218^th place

190^th place

4biontech.de

low place

4worldcat.org

5^th place

26^th place

3europa.eu

68^th place

44^th place

2nytimes.com

7^th place

29^th place

2gov.uk

432^nd place

1,602^nd place

2theguardian.com

12^th place

53^rd place

1cnbc.com

220^th place

535^th place

1canada.ca

1,712^th place

7,268^th place

1clinicaltrials.gov

5,225^th place

low place

1npr.org

92^nd place

197^th place

1statnews.com

8,771^st place

low place

1webmd.com

1,169^th place

898^th place

1go.com

48^th place

119^th place

1cvdvaccine-us.com

low place

1nhs.uk

1,989^th place

1,655^th place

1admin.ch

279^th place

210^th place

1trackvaccines.org

low place

1health.gov.au

low place

1cnn.com

28^th place

63^rd place

1pfizer.com

low place

1bloomberg.com

99^th place

335^th place

1books.google.com

3^rd place

6^th place

1wsj.com

79^th place

365^th place

1medicines.org.uk

3,823^rd place

low place

1semanticscholar.org

11^th place

148^th place

admin.ch (Global: 279^th place; Georgian: 210^th place)

bag.admin.ch

„Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland“ (პრეს-რელიზი). Swiss Agency for Therapeutic Products (Swissmedic). 19 December 2020. დაარქივებულია ორიგინალიდან — 10 January 2021. ციტირების თარიღი: 19 December 2020.

biontech.de (Global: low place; Georgian: low place)

investors.biontech.de

„Update on our COVID-19 vaccine development program with BNT162b2“ (PDF) (პრეს-რელიზი). BioNTech. 2 December 2020. დაარქივებულია ორიგინალიდან — 3 December 2020. ციტირების თარიღი: 12 December 2020.
„Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study“. BioNTech (პრეს-რელიზი). 1 April 2021. დაარქივებულია ორიგინალიდან — 4 April 2021. ციტირების თარიღი: 11 April 2021.
„Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of Comirnaty“ (პრეს-რელიზი). BioNTech. 17 February 2021. დაარქივებულია ორიგინალიდან — 26 February 2021. ციტირების თარიღი: 1 March 2021.
„Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine“ (პრეს-რელიზი). BioNTech. 21 October 2021. ციტირების თარიღი: 10 November 2021.

bloomberg.com (Global: 99^th place; Georgian: 335^th place)

Kresge N (30 March 2021). „BioNTech Raises Covid Vaccine Target to 2.5 Billion Doses“. Bloomberg. დაარქივებულია ორიგინალიდან — 11 April 2021. ციტირების თარიღი: 11 April 2021.

books.google.com (Global: 3^rd place; Georgian: 6^th place)

Rosales-Mendoza, Sergio; Wong-Arse, Alejandro; de Lourdes.Betancourt-Mendiola, Maria (2021) „8. RNA based vaccines against SARS COV-2“, Biomedical Innovations to Combat COVID-19 (en). London: Academic Press, გვ. 129–152. ISBN 978-0-323-90248-9.

canada.ca (Global: 1,712^th place; Georgian: 7,268^th place)

covid-vaccine.canada.ca

Regulatory Decision Summary - Pfizer-BioNTech COVID-19 Vaccine. Health Canada. ციტირების თარიღი: 11 May 2021

cdc.gov (Global: 218^th place; Georgian: 190^th place)

„CDC Recommends Pediatric COVID-19 Vaccine for Children 5 to 11 Years“. U.S. Centers for Disease Control and Prevention (CDC) (პრეს-რელიზი). 2 November 2021. ციტირების თარიღი: 4 November 2021.
Pfizer–BioNTech COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 12 Years of Age and Older. U.S. Centers for Disease Control and Prevention (CDC) (28 September 2021). ციტირების თარიღი: 24 October 2021
Pfizer-BioNTech COVID-19 Vaccine (also known as Comirnaty) Overview and Safety (19 November 2021). ციტირების თარიღი: 27 September 2021
COVID-19 Vaccines for Moderately or Severely Immunocompromised People (13 August 2021). ციტირების თარიღი: 13 August 2021
Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K (27 August 2021). „Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021“ (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (34): 1167–9. doi:10.15585/mmwr.mm7034e4. PMC 8389394. PMID 34437521.

clinicaltrials.gov (Global: 5,225^th place; Georgian: low place)

„Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals“. ClinicalTrials.gov. 30 April 2020. დაარქივებულია ორიგინალიდან — 11 October 2020. ციტირების თარიღი: 5 August 2021.

cnbc.com (Global: 220^th place; Georgian: 535^th place)

Browne R (11 November 2020). „What you need to know about BioNTech – the European company behind Pfizer's Covid-19 vaccine“. CNBC. დაარქივებულია ორიგინალიდან — 4 March 2021. ციტირების თარიღი: 14 January 2021.

cnn.com (Global: 28^th place; Georgian: 63^rd place)

Howard J (23 August 2021). „FDA grants full approval to Pfizer/BioNTech Covid-19 vaccine, opening door to more vaccine mandates“. CNN. ციტირების თარიღი: 23 August 2021.

cvdvaccine-us.com (Global: low place; Georgian: low place)

Questions and Answers About Pfizer–BioNTech COVID-19 Vaccine. Pfizer. დაარქივებულია ორიგინალიდან — 24 იანვარი 2021. ციტირების თარიღი: 16 December 2020

doi.org (Global: 2^nd place; Georgian: 7^th place)

Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. (October 2020). „Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates“. The New England Journal of Medicine. 383 (25): 2439–50. doi:10.1056/NEJMoa2027906. PMC 7583697. PMID 33053279.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. (December 2020). „Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine“. N Engl J Med. 383 (27): 2603–15. doi:10.1056/NEJMoa2034577. PMC 7745181. PMID 33301246.
Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. (August 2021). „Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant“. The New England Journal of Medicine. 385 (7): 585–594. doi:10.1056/NEJMoa2108891. PMC 8314739. PMID 34289274.
Evans SJ, Jewell NP (August 2021). „Vaccine Effectiveness Studies in the Field“. The New England Journal of Medicine. 385 (7): 650–651. doi:10.1056/NEJMe2110605. PMC 8314732. PMID 34289269.
Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K (27 August 2021). „Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021“ (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (34): 1167–9. doi:10.15585/mmwr.mm7034e4. PMC 8389394. PMID 34437521.
Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R, Dean NE, et al. (12 September 2020). „COVID-19 vaccine trials should seek worthwhile efficacy“. The Lancet. 396 (10253): 741–743. doi:10.1016/S0140-6736(20)31821-3. ISSN 0140-6736. PMC 7832749. PMID 32861315. ციტატა: „WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Guidance from the US Food and Drug Administration includes this lower limit of 30% as a criterion for vaccine licensure.“
Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. (May 2021). „Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection“. Nature Medicine. 27 (7): 1205–11. doi:10.1038/s41591-021-01377-8. PMID 34002089. S2CID 234769053.
Sheikh A, McMenamin J, Taylor B, Robertson C (14 June 2021). „SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness“. The Lancet. 397 (10293). Table S4. doi:10.1016/S0140-6736(21)01358-1. ISSN 0140-6736. PMC 8201647. PMID 34139198.
Abu-Raddad LJ, Chemaitelly H, Butt AA (5 May 2021). „Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants“. New England Journal of Medicine. 385 (2). Table 1. doi:10.1056/NEJMc2104974. ISSN 0028-4793. PMC 8117967. PMID 33951357.
Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. (August 2021). „Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study“. BMJ. 374: n1943. doi:10.1136/bmj.n1943. PMC 8377789. PMID 34417165. ციტატა: „Tables 6 and 7“
Collie S, Champion J, Moultrie H, Bekker LG, Gray G (December 2021). „Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa“. N Engl J Med (letter). doi:10.1056/NEJMc2119270. PMC 8757569. PMID 34965358.
Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. (September 2021). „Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months“. The New England Journal of Medicine. 385 (19): 1761–1773. doi:10.1056/nejmoa2110345. PMC 8461570. PMID 34525277.
Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, et al. (6 October 2021). „Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar“. New England Journal of Medicine. 385 (24): e83. doi:10.1056/NEJMoa2114114. ISSN 0028-4793. PMC 8522799. PMID 34614327.

europa.eu (Global: 68^th place; Georgian: 44^th place)

ema.europa.eu

Comirnaty EPAR. ციტირების თარიღი: 24 October 2021
„First COVID-19 vaccine approved for children aged 12 to 15 in EU“. European Medicines Agency (EMA) (პრეს-რელიზი). 28 May 2021. დაარქივებულია ორიგინალიდან — 28 May 2021. ციტირების თარიღი: 29 May 2021.
Comirnaty and Spikevax: EMA recommendations on extra doses and boosters (4 October 2021). ციტირების თარიღი: 4 October 2021

fda.gov (Global: 447^th place; Georgian: 1,705^th place)

„FDA Approves First COVID-19 Vaccine“ (პრეს-რელიზი). U.S. Food and Drug Administration (FDA). 23 August 2021. დაარქივებულია ორიგინალიდან — 23 August 2021. ციტირების თარიღი: 23 August 2021.
Pfizer–BioNTech COVID-19 Vaccine. U.S. Food and Drug Administration (FDA) (3 February 2021). ციტირების თარიღი: 5 February 2021
Comirnaty (23 August 2021). ციტირების თარიღი: 23 August 2021
Pfizer–BioNTech COVID-19 Vaccine Emergency Use Authorization Review Memorandum (PDF) (14 December 2020). ციტირების თარიღი: 14 December 2020 თარგი:PD-notice
„Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals“. U.S. Food and Drug Administration (FDA) (პრეს-რელიზი). 12 August 2021. დაარქივებულია ორიგინალიდან — 7 December 2021. ციტირების თარიღი: 13 August 2021.

go.com (Global: 48^th place; Georgian: 119^th place)

abcnews.go.com

„Canada vaccine panel recommends 4 months between COVID doses“. ABC News. 4 March 2021. დაარქივებულია ორიგინალიდან — 26 July 2021. ციტირების თარიღი: 9 July 2021.

gov.uk (Global: 432^nd place; Georgian: 1,602^nd place)

Information for UK recipients on Pfizer/BioNTech COVID-19 vaccine. Medicines and Healthcare products Regulatory Agency (MHRA) (8 December 2020). ციტირების თარიღი: 29 May 2021
„UK medicines regulator gives approval for first UK COVID-19 vaccine“ (პრეს-რელიზი). Medicines and Healthcare products Regulatory Agency (MHRA). 2 December 2020. დაარქივებულია ორიგინალიდან — 17 March 2021. ციტირების თარიღი: 2 December 2020.

health.gov.au (Global: low place; Georgian: low place)

Australian Government Department of Health. (24 January 2021) About the Pfizer/BioNTech COVID-19 vaccine. ციტირების თარიღი: 31 May 2021

medicines.org.uk (Global: 3,823^rd place; Georgian: low place)

Comirnaty 30 micrograms/dose concentrate for dispersion for injection 12+ years COVID-19 mRNA Vaccine (nucleoside modified) - Summary of Product Characteristics (SmPC). დაარქივებულია ორიგინალიდან — 4 თებერვალი 2022. ციტირების თარიღი: 4 February 2022

nhs.uk (Global: 1,989^th place; Georgian: 1,655^th place)

Coronavirus vaccine. National Health Service (7 December 2020). ციტირების თარიღი: 7 December 2020

nih.gov (Global: 4^th place; Georgian: 8^th place)

pubmed.ncbi.nlm.nih.gov

Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. (October 2020). „Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates“. The New England Journal of Medicine. 383 (25): 2439–50. doi:10.1056/NEJMoa2027906. PMC 7583697. PMID 33053279.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. (December 2020). „Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine“. N Engl J Med. 383 (27): 2603–15. doi:10.1056/NEJMoa2034577. PMC 7745181. PMID 33301246.
Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. (August 2021). „Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant“. The New England Journal of Medicine. 385 (7): 585–594. doi:10.1056/NEJMoa2108891. PMC 8314739. PMID 34289274.
Evans SJ, Jewell NP (August 2021). „Vaccine Effectiveness Studies in the Field“. The New England Journal of Medicine. 385 (7): 650–651. doi:10.1056/NEJMe2110605. PMC 8314732. PMID 34289269.
Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K (27 August 2021). „Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021“ (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (34): 1167–9. doi:10.15585/mmwr.mm7034e4. PMC 8389394. PMID 34437521.
Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R, Dean NE, et al. (12 September 2020). „COVID-19 vaccine trials should seek worthwhile efficacy“. The Lancet. 396 (10253): 741–743. doi:10.1016/S0140-6736(20)31821-3. ISSN 0140-6736. PMC 7832749. PMID 32861315. ციტატა: „WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Guidance from the US Food and Drug Administration includes this lower limit of 30% as a criterion for vaccine licensure.“
Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. (May 2021). „Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection“. Nature Medicine. 27 (7): 1205–11. doi:10.1038/s41591-021-01377-8. PMID 34002089. S2CID 234769053.
Sheikh A, McMenamin J, Taylor B, Robertson C (14 June 2021). „SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness“. The Lancet. 397 (10293). Table S4. doi:10.1016/S0140-6736(21)01358-1. ISSN 0140-6736. PMC 8201647. PMID 34139198.
Abu-Raddad LJ, Chemaitelly H, Butt AA (5 May 2021). „Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants“. New England Journal of Medicine. 385 (2). Table 1. doi:10.1056/NEJMc2104974. ISSN 0028-4793. PMC 8117967. PMID 33951357.
Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. (August 2021). „Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study“. BMJ. 374: n1943. doi:10.1136/bmj.n1943. PMC 8377789. PMID 34417165. ციტატა: „Tables 6 and 7“
Collie S, Champion J, Moultrie H, Bekker LG, Gray G (December 2021). „Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa“. N Engl J Med (letter). doi:10.1056/NEJMc2119270. PMC 8757569. PMID 34965358.
Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. (September 2021). „Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months“. The New England Journal of Medicine. 385 (19): 1761–1773. doi:10.1056/nejmoa2110345. PMC 8461570. PMID 34525277.
Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, et al. (6 October 2021). „Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar“. New England Journal of Medicine. 385 (24): e83. doi:10.1056/NEJMoa2114114. ISSN 0028-4793. PMC 8522799. PMID 34614327.

ncbi.nlm.nih.gov

Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. (October 2020). „Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates“. The New England Journal of Medicine. 383 (25): 2439–50. doi:10.1056/NEJMoa2027906. PMC 7583697. PMID 33053279.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. (December 2020). „Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine“. N Engl J Med. 383 (27): 2603–15. doi:10.1056/NEJMoa2034577. PMC 7745181. PMID 33301246.
Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. (August 2021). „Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant“. The New England Journal of Medicine. 385 (7): 585–594. doi:10.1056/NEJMoa2108891. PMC 8314739. PMID 34289274.
Evans SJ, Jewell NP (August 2021). „Vaccine Effectiveness Studies in the Field“. The New England Journal of Medicine. 385 (7): 650–651. doi:10.1056/NEJMe2110605. PMC 8314732. PMID 34289269.
Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K (27 August 2021). „Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021“ (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (34): 1167–9. doi:10.15585/mmwr.mm7034e4. PMC 8389394. PMID 34437521.
Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R, Dean NE, et al. (12 September 2020). „COVID-19 vaccine trials should seek worthwhile efficacy“. The Lancet. 396 (10253): 741–743. doi:10.1016/S0140-6736(20)31821-3. ISSN 0140-6736. PMC 7832749. PMID 32861315. ციტატა: „WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Guidance from the US Food and Drug Administration includes this lower limit of 30% as a criterion for vaccine licensure.“
Sheikh A, McMenamin J, Taylor B, Robertson C (14 June 2021). „SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness“. The Lancet. 397 (10293). Table S4. doi:10.1016/S0140-6736(21)01358-1. ISSN 0140-6736. PMC 8201647. PMID 34139198.
Abu-Raddad LJ, Chemaitelly H, Butt AA (5 May 2021). „Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants“. New England Journal of Medicine. 385 (2). Table 1. doi:10.1056/NEJMc2104974. ISSN 0028-4793. PMC 8117967. PMID 33951357.
Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. (August 2021). „Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study“. BMJ. 374: n1943. doi:10.1136/bmj.n1943. PMC 8377789. PMID 34417165. ციტატა: „Tables 6 and 7“
Collie S, Champion J, Moultrie H, Bekker LG, Gray G (December 2021). „Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa“. N Engl J Med (letter). doi:10.1056/NEJMc2119270. PMC 8757569. PMID 34965358.
Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. (September 2021). „Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months“. The New England Journal of Medicine. 385 (19): 1761–1773. doi:10.1056/nejmoa2110345. PMC 8461570. PMID 34525277.
Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, et al. (6 October 2021). „Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar“. New England Journal of Medicine. 385 (24): e83. doi:10.1056/NEJMoa2114114. ISSN 0028-4793. PMC 8522799. PMID 34614327.

dailymed.nlm.nih.gov

Pfizer-Biontech COVID-19 Vaccine- bnt162b2 injection, suspension. ციტირების თარიღი: 24 October 2021
Comirnaty- covid-19 vaccine, mrna injection, suspension. ციტირების თარიღი: 4 February 2022

npr.org (Global: 92^nd place; Georgian: 197^th place)

Palca J (9 November 2020). „Pfizer says experimental COVID-19 vaccine is more than 90% effective“. NPR.org. NPR. დაარქივებულია ორიგინალიდან — 9 November 2020. ციტირების თარიღი: 9 November 2020.

nytimes.com (Global: 7^th place; Georgian: 29^th place)

Thomas K, Gelles D, Zimmer C (9 November 2020). „Pfizer's early data shows vaccine is more than 90% effective“. The New York Times. დაარქივებულია ორიგინალიდან — 23 November 2020. ციტირების თარიღი: 9 November 2020.
F.D.A. Clears Pfizer Vaccine, and Millions of Doses Will Be Shipped Right Away (20 November 2020).

pfizer.com (Global: low place; Georgian: low place)

Pfizer and BioNTech expand collaboration with U.S. to provide 500 million additional COVID-19 vaccine doses at not-for-profit price for donation to poorest countries (22 September 2021).

semanticscholar.org (Global: 11^th place; Georgian: 148^th place)

api.semanticscholar.org

Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. (May 2021). „Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection“. Nature Medicine. 27 (7): 1205–11. doi:10.1038/s41591-021-01377-8. PMID 34002089. S2CID 234769053.

statnews.com (Global: 8,771^st place; Georgian: low place)

Covid-19 vaccine from Pfizer and BioNTech is strongly effective, early data from large trial indicate. Stat News (9 November 2020). ციტირების თარიღი: 9 November 2020

theguardian.com (Global: 12^th place; Georgian: 53^rd place)

Boseley S, Halliday J (2 December 2020). „UK approves Pfizer/BioNTech Covid vaccine for rollout next week“. The Guardian. დაარქივებულია ორიგინალიდან — 2 December 2020. ციტირების თარიღი: 14 December 2020.
„Pfizer vaccine second dose has 'sweet spot' after eight weeks, UK scientists say“. 23 July 2021. დაარქივებულია ორიგინალიდან — 18 November 2021. ციტირების თარიღი: 26 July 2021.

trackvaccines.org (Global: low place; Georgian: low place)

covid19.trackvaccines.org

COVID-19 Vaccine Tracker: Pfizer/BioNTech: BNT162b2. McGill University. დაარქივებულია ორიგინალიდან — 8 მაისი 2021. ციტირების თარიღი: 8 May 2021

web.archive.org (Global: 1^st place; Georgian: 1^st place)

„FDA Approves First COVID-19 Vaccine“ (პრეს-რელიზი). U.S. Food and Drug Administration (FDA). 23 August 2021. დაარქივებულია ორიგინალიდან — 23 August 2021. ციტირების თარიღი: 23 August 2021.
Browne R (11 November 2020). „What you need to know about BioNTech – the European company behind Pfizer's Covid-19 vaccine“. CNBC. დაარქივებულია ორიგინალიდან — 4 March 2021. ციტირების თარიღი: 14 January 2021.
Thomas K, Gelles D, Zimmer C (9 November 2020). „Pfizer's early data shows vaccine is more than 90% effective“. The New York Times. დაარქივებულია ორიგინალიდან — 23 November 2020. ციტირების თარიღი: 9 November 2020.
„First COVID-19 vaccine approved for children aged 12 to 15 in EU“. European Medicines Agency (EMA) (პრეს-რელიზი). 28 May 2021. დაარქივებულია ორიგინალიდან — 28 May 2021. ციტირების თარიღი: 29 May 2021.
„Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals“. ClinicalTrials.gov. 30 April 2020. დაარქივებულია ორიგინალიდან — 11 October 2020. ციტირების თარიღი: 5 August 2021.
Palca J (9 November 2020). „Pfizer says experimental COVID-19 vaccine is more than 90% effective“. NPR.org. NPR. დაარქივებულია ორიგინალიდან — 9 November 2020. ციტირების თარიღი: 9 November 2020.
„Canada vaccine panel recommends 4 months between COVID doses“. ABC News. 4 March 2021. დაარქივებულია ორიგინალიდან — 26 July 2021. ციტირების თარიღი: 9 July 2021.
„Update on our COVID-19 vaccine development program with BNT162b2“ (PDF) (პრეს-რელიზი). BioNTech. 2 December 2020. დაარქივებულია ორიგინალიდან — 3 December 2020. ციტირების თარიღი: 12 December 2020.
„Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study“. BioNTech (პრეს-რელიზი). 1 April 2021. დაარქივებულია ორიგინალიდან — 4 April 2021. ციტირების თარიღი: 11 April 2021.
Questions and Answers About Pfizer–BioNTech COVID-19 Vaccine. Pfizer. დაარქივებულია ორიგინალიდან — 24 იანვარი 2021. ციტირების თარიღი: 16 December 2020
„UK medicines regulator gives approval for first UK COVID-19 vaccine“ (პრეს-რელიზი). Medicines and Healthcare products Regulatory Agency (MHRA). 2 December 2020. დაარქივებულია ორიგინალიდან — 17 March 2021. ციტირების თარიღი: 2 December 2020.
Boseley S, Halliday J (2 December 2020). „UK approves Pfizer/BioNTech Covid vaccine for rollout next week“. The Guardian. დაარქივებულია ორიგინალიდან — 2 December 2020. ციტირების თარიღი: 14 December 2020.
„Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland“ (პრეს-რელიზი). Swiss Agency for Therapeutic Products (Swissmedic). 19 December 2020. დაარქივებულია ორიგინალიდან — 10 January 2021. ციტირების თარიღი: 19 December 2020.
COVID-19 Vaccine Tracker: Pfizer/BioNTech: BNT162b2. McGill University. დაარქივებულია ორიგინალიდან — 8 მაისი 2021. ციტირების თარიღი: 8 May 2021
„Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of Comirnaty“ (პრეს-რელიზი). BioNTech. 17 February 2021. დაარქივებულია ორიგინალიდან — 26 February 2021. ციტირების თარიღი: 1 March 2021.
Kresge N (30 March 2021). „BioNTech Raises Covid Vaccine Target to 2.5 Billion Doses“. Bloomberg. დაარქივებულია ორიგინალიდან — 11 April 2021. ციტირების თარიღი: 11 April 2021.
Hopkins JS (30 March 2021). „Pfizer to Test Covid-19 Vaccine That Doesn't Need Ultracold Storage“. The Wall Street Journal. დაარქივებულია ორიგინალიდან — 15 May 2021. ციტირების თარიღი: 16 May 2021.
Comirnaty 30 micrograms/dose concentrate for dispersion for injection 12+ years COVID-19 mRNA Vaccine (nucleoside modified) - Summary of Product Characteristics (SmPC). დაარქივებულია ორიგინალიდან — 4 თებერვალი 2022. ციტირების თარიღი: 4 February 2022
„Pfizer vaccine second dose has 'sweet spot' after eight weeks, UK scientists say“. 23 July 2021. დაარქივებულია ორიგინალიდან — 18 November 2021. ციტირების თარიღი: 26 July 2021.
„Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals“. U.S. Food and Drug Administration (FDA) (პრეს-რელიზი). 12 August 2021. დაარქივებულია ორიგინალიდან — 7 December 2021. ციტირების თარიღი: 13 August 2021.

webmd.com (Global: 1,169^th place; Georgian: 898^th place)

CDC: Gap Between Vaccine Doses Could Be 6 Weeks. ციტირების თარიღი: 8 July 2021

worldcat.org (Global: 5^th place; Georgian: 26^th place)

Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R, Dean NE, et al. (12 September 2020). „COVID-19 vaccine trials should seek worthwhile efficacy“. The Lancet. 396 (10253): 741–743. doi:10.1016/S0140-6736(20)31821-3. ISSN 0140-6736. PMC 7832749. PMID 32861315. ციტატა: „WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Guidance from the US Food and Drug Administration includes this lower limit of 30% as a criterion for vaccine licensure.“
Sheikh A, McMenamin J, Taylor B, Robertson C (14 June 2021). „SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness“. The Lancet. 397 (10293). Table S4. doi:10.1016/S0140-6736(21)01358-1. ISSN 0140-6736. PMC 8201647. PMID 34139198.
Abu-Raddad LJ, Chemaitelly H, Butt AA (5 May 2021). „Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants“. New England Journal of Medicine. 385 (2). Table 1. doi:10.1056/NEJMc2104974. ISSN 0028-4793. PMC 8117967. PMID 33951357.
Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, et al. (6 October 2021). „Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar“. New England Journal of Medicine. 385 (24): e83. doi:10.1056/NEJMoa2114114. ISSN 0028-4793. PMC 8522799. PMID 34614327.

wsj.com (Global: 79^th place; Georgian: 365^th place)

Hopkins JS (30 March 2021). „Pfizer to Test Covid-19 Vaccine That Doesn't Need Ultracold Storage“. The Wall Street Journal. დაარქივებულია ორიგინალიდან — 15 May 2021. ციტირების თარიღი: 16 May 2021.

Pfizer–BioNTech-ის COVID-19-ის საწინააღმდეგო ვაქცინა (Georgian Wikipedia)

admin.ch (Global: 279th place; Georgian: 210th place)

bag.admin.ch

biontech.de (Global: low place; Georgian: low place)

investors.biontech.de

bloomberg.com (Global: 99th place; Georgian: 335th place)

books.google.com (Global: 3rd place; Georgian: 6th place)

canada.ca (Global: 1,712th place; Georgian: 7,268th place)

covid-vaccine.canada.ca

cdc.gov (Global: 218th place; Georgian: 190th place)

clinicaltrials.gov (Global: 5,225th place; Georgian: low place)

cnbc.com (Global: 220th place; Georgian: 535th place)

cnn.com (Global: 28th place; Georgian: 63rd place)

cvdvaccine-us.com (Global: low place; Georgian: low place)

doi.org (Global: 2nd place; Georgian: 7th place)

europa.eu (Global: 68th place; Georgian: 44th place)

ema.europa.eu

fda.gov (Global: 447th place; Georgian: 1,705th place)

go.com (Global: 48th place; Georgian: 119th place)

abcnews.go.com

gov.uk (Global: 432nd place; Georgian: 1,602nd place)

health.gov.au (Global: low place; Georgian: low place)

medicines.org.uk (Global: 3,823rd place; Georgian: low place)

nhs.uk (Global: 1,989th place; Georgian: 1,655th place)

nih.gov (Global: 4th place; Georgian: 8th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

npr.org (Global: 92nd place; Georgian: 197th place)

nytimes.com (Global: 7th place; Georgian: 29th place)

pfizer.com (Global: low place; Georgian: low place)

semanticscholar.org (Global: 11th place; Georgian: 148th place)

api.semanticscholar.org

statnews.com (Global: 8,771st place; Georgian: low place)

theguardian.com (Global: 12th place; Georgian: 53rd place)

trackvaccines.org (Global: low place; Georgian: low place)

covid19.trackvaccines.org

web.archive.org (Global: 1st place; Georgian: 1st place)

webmd.com (Global: 1,169th place; Georgian: 898th place)

worldcat.org (Global: 5th place; Georgian: 26th place)

wsj.com (Global: 79th place; Georgian: 365th place)

admin.ch (Global: 279^th place; Georgian: 210^th place)

bloomberg.com (Global: 99^th place; Georgian: 335^th place)

books.google.com (Global: 3^rd place; Georgian: 6^th place)

canada.ca (Global: 1,712^th place; Georgian: 7,268^th place)

cdc.gov (Global: 218^th place; Georgian: 190^th place)

clinicaltrials.gov (Global: 5,225^th place; Georgian: low place)

cnbc.com (Global: 220^th place; Georgian: 535^th place)

cnn.com (Global: 28^th place; Georgian: 63^rd place)

doi.org (Global: 2^nd place; Georgian: 7^th place)

europa.eu (Global: 68^th place; Georgian: 44^th place)

fda.gov (Global: 447^th place; Georgian: 1,705^th place)

go.com (Global: 48^th place; Georgian: 119^th place)

gov.uk (Global: 432^nd place; Georgian: 1,602^nd place)

medicines.org.uk (Global: 3,823^rd place; Georgian: low place)

nhs.uk (Global: 1,989^th place; Georgian: 1,655^th place)

nih.gov (Global: 4^th place; Georgian: 8^th place)

npr.org (Global: 92^nd place; Georgian: 197^th place)

nytimes.com (Global: 7^th place; Georgian: 29^th place)

semanticscholar.org (Global: 11^th place; Georgian: 148^th place)

statnews.com (Global: 8,771^st place; Georgian: low place)

theguardian.com (Global: 12^th place; Georgian: 53^rd place)

web.archive.org (Global: 1^st place; Georgian: 1^st place)

webmd.com (Global: 1,169^th place; Georgian: 898^th place)

worldcat.org (Global: 5^th place; Georgian: 26^th place)

wsj.com (Global: 79^th place; Georgian: 365^th place)